What is ProSomnus Sleep Technologies?
Founded in 2016 and headquartered in Pleasanton, California, ProSomnus Sleep Technologies is a premier manufacturer of precision, patient-preferred Oral Appliance Therapy (OAT) medical devices. The company specializes in the treatment of Obstructive Sleep Apnea, a condition that affects millions globally. By focusing on high-precision manufacturing and patient-centric design, ProSomnus has established itself as a critical player in the sleep health ecosystem. Their devices are engineered to provide a comfortable, effective alternative to traditional CPAP therapy, thereby improving patient compliance and long-term health outcomes. The firm's market position is bolstered by its rigorous adherence to clinical standards and its ability to integrate advanced materials science into medical device production.
How much funding has ProSomnus Sleep Technologies raised?
ProSomnus Sleep Technologies has raised a total of $50M across 4 funding rounds:
Debt
$1M
Debt
$1M
Private Equity
$10M
Unspecified
$38M
Debt (2020): $1M with participation from PPP
Debt (2021): $1M led by PPP
Private Equity (2023): $10M supported by Cetus Capital Partners and Spring Mountain Capital
Unspecified (2026): $38M featuring Catalio Capital Management
Key Investors in ProSomnus Sleep Technologies
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, with a focus on breakthrough biomedical technology.
Cetus Capital Partners
Cetus Capital Partners specializes in structured finance and commodity trade finance solutions, leveraging extensive industry experience to provide consulting and capital facilities.
Spring Mountain Capital
Spring Mountain Capital specializes in various investment strategies including growth equity, private capital, and healthcare investing, providing expansion capital for enterprise technology and healthcare companies.
What's next for ProSomnus Sleep Technologies?
With the influx of $38M, ProSomnus is well-positioned to accelerate its commercial expansion and deepen its research and development capabilities. The strategic focus will likely shift toward scaling manufacturing capacity to meet rising global demand for non-invasive OSA treatments and potentially expanding its clinical footprint into new international markets. Furthermore, the involvement of specialized healthcare investors suggests a long-term strategy centered on building a category-defining business that bridges the gap between biomedical innovation and clinical application. As the company matures, the focus will remain on maintaining its competitive edge through technological differentiation and strategic partnerships within the broader healthcare landscape.
See full ProSomnus Sleep Technologies company page
